Genxone (WAR:GX1) Altman Z2-Score: 18.11 (As of Jul. 22, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GX1 Genxone SA WAR:GX1
66 GF Score
Price zł5.68
GF Value zł6.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genxone Altman Z2-Score?

Genxone WAR:GX1 -0.35% 66 Altman Z2-Score is 18.11 as of Jul. 22, 2026, which is 1% below its 10-year median of 18.37. GuruFocus rates WAR:GX1 with a GF Score™ of 66/100 and a GF Value™ of zł6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,390 Biotechnology companies, Genxone ranks better than 92.37% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Genxone has a Altman Z2-Score of 18.11, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Genxone's Altman Z2-Score or its related term are showing as below:

WAR:GX1' s Altman Z2-Score Range Over the Past 10 Years
Min: -2.47   Med: 18.37   Max: 34.24
Current: 18.11

During the past 8 years, Genxone's highest Altman Z2-Score was 34.24. The lowest was -2.47. And the median was 18.37.


Genxone  (WAR:GX1) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Genxone Altman Z2-Score Related Terms


Genxone Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Genxone's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genxone Altman Z2-Score Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 13.90 22.21 30.74 18.37 16.02

Genxone Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.43 18.38 22.80 16.02 18.11

WAR:GX1 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Genxone's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genxone Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genxone's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Genxone's Altman Z2-Score falls into.


WAR:GX1
66GF Score
Genxone SA WAR:GX1
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genxone Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Genxone's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3885+3.26*-0.3783+6.72*-0.2298+1.05*17.4624
=18.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was zł8.35 Mil.
Total Current Assets was zł3.69 Mil.
Total Current Liabilities was zł0.45 Mil.
Retained Earnings was zł-3.16 Mil.
Pre-Tax Income was -0.513 + -0.207 + -0.636 + -0.57 = zł-1.93 Mil.
Interest Expense was 0 + -0.006 + -0.002 + 0 = zł-0.01 Mil.
Total Liabilities was zł0.45 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3.694 - 0.452)/8.345
=0.3885

X2=Retained Earnings/Total Assets
=-3.157/8.345
=-0.3783

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1.926 - -0.008)/8.345
=-0.2298

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(7.893 - 0)/0.452
=17.4624

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Genxone has a Altman Z2-Score of 18.11 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 18.11 mean?
Genxone (WAR:GX1) has a Altman Z2-Score of 18.11 as of Jul. 22, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Genxone and its competitors. This is near median its historical median of 18.37. According to the industry distribution chart, Genxone ranks #106 out of 1390 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Genxone's Altman Z2-Score too high?
Genxone's current Altman Z2-Score of 18.11 is near median its 10-year median of 18.37. Based on the distribution chart, Genxone ranks #106 out of 1390 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genxone has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genxone ranks #106 out of 1390 companies for Altman Z2-Score. This places Genxone in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Genxone and its competitors. Genxone's current Altman Z2-Score is 18.11, which is near median its own 10-year median of 18.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.51, compared to a current price of zł5.68 — trading 12.7% below its estimated fair value. The current Altman Z2-Score is 18.11, which is near median its 10-year median of 18.37. Genxone's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Altman Z2-Score is 18.11 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genxone (WAR:GX1) Overvalued in 2026?

Based on GuruFocus' analysis, Genxone stock appears to be undervalued. The current stock price of zł5.68 is trading 12.7% below its estimated GF Value™ of zł6.51. GuruFocus considers Genxone to be Modestly Undervalued.

Key valuation signals for WAR:GX1:

  • Altman Z2-Score: 18.11 (near median its 10-year median of 18.37)
  • GF Value™: zł6.51 vs. price of zł5.68 (12.7% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genxone Business Description

Address Kobaltowa Street 6, Zlotniki, POL, 62002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
66GF Score

Get the complete analysis for WAR:GX1

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.68
Price
zł6.51
GF Value